Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less - 2The Best Competitors of the 21st Hundred years
- 3Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- 4A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- 5Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- PHOTO ESSAY: Summer camp for kids with autoimmune diseases
- The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs
- Satellite data reveals a huge solar storm in 2024 shrank Earth's protective plasma shield
- NASA shares first photos of Earth taken by Artemis II
- 'Harry Potter' fans rejoice: HBO releases 1st trailer for new TV series, set to premiere this Christmas
- German politician urges more face-to-face interaction in digital age
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
